MESO (Mesoblast Limited) Earnings per share growth rate in current year

Official company branding of Mesoblast Limited (MESO)

Mesoblast Limited (MESO) is implementing ESG principles by optimizing cryostorage energy consumption and research bioethics. This annual earnings per share chart from the GURU.Markets platform demonstrates volatility, where the value of 64.90 serves as the baseline indicator. However, the risk of FDA rejections and equity dilution concern investors, despite the company's status as a scientific innovator and high patient confidence in cell therapy.

MESO Mesoblast Limited Earnings per share growth in current year (07/04/2022 - 11/15/2026)

Analytical breakdowns and data insights for company Mesoblast (MESO)

- price and consensus price forecast:
Stock Quotes Mesoblast Corp|MESO - Analyst Consensus Forecast
- business market valuation indicators:
Market Value Mesoblast Limited|MESO - Total Company Value
- balance sheet equity data:
Net Assets per Share Mesoblast|MESO - Company Book Value|Market-to-Book Ratio mesoblast.com|MESO - Company Total Assets
- debt and liquidity details:
Debt to Equity Mesoblast Limited|MESO - Long-Term Debt to Equity|Short-Term Debt to Equity Mesoblast|MESO - Company Aggregate Debts|Debts to Book Capitalization Mesoblast Limited|MESO - Company Long-Term Debt|Short-Term Debt Volume Mesoblast|Intermediate Liquidity Ratio mesoblast.com
- earnings and multiples data:
MESO - Net Income|Expected Net Income Mesoblast Limited|MESO - Price to Earnings Ratio|Future Price to Earnings Mesoblast Limited|MESO - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Mesoblast Limited|MESO - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Mesoblast|MESO - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months mesoblast.com|MESO - Net earnings per share growth this year|Projected earnings per share increase next year Mesoblast Limited
- revenue and sales proceeds data:
MESO - Revenue and Sales Volume|Company Expected Sales Volume Mesoblast Corp|MESO - P/S Multiple|Market Cap to Projected Revenue Mesoblast Limited
Fundamental valuation:Mesoblast Limited
Finished products of mesoblast.com

The YoY earnings per share growth rate reflects the progress of Mesoblast Limited (MESO) in monetizing cell technologies amid costly clinical trials and the search for strategic partners. This metric is calculated as the percentage deviation of the current EPS from the previous year's value, measuring the business's actual ability to generate income, where any decline signals risks of investor capital freeze.

Main competitors

LCTX (Lineage Bio) - Earnings per share growth in current year|Net earnings per share growth this year SRZN|CCEL: Earnings per share increase in current year|Earnings growth in current year FBLG|Longeveron - Earnings per share growth this year|Earnings per share growth in current year BioRestorative Therapies BRTX|Earnings growth in current year creativemedicaltechnology.com CELZ